Nordic Capital and Five Arrows to sell The Binding Site, a global leader in specialty diagnostics
· The Binding Site has grown significantly under Nordic Capital’s and Five Arrows’ ownership, creating an industry leader in oncology testing for detection and monitoring of Multiple MyelomaNordic Capital and Five Arrows have entered into a definitive agreement to sell The Binding Site, a global leader in specialty diagnostics, to Thermo Fisher Scientific (NYSE:TMO), the world leader in serving science. The transaction is valued at GBP 2.25 billion. Since the acquisition of The Binding Site in 2011, the business has made an impressive transformation from a founder-led research-based